events
30 November 2018
Da Volterra at J.P. Morgan Healthcare Conference in SFO!
Meet Florence Séjourné, CEO of Da Volterra, at J.P. Morgan Healthcare Conference, the largest and most informative Healthcare Investment Symposium…
The US Patent and Trademark Office has recently granted a new patent for Da Volterra in the USA. The patent received number 9,968,562 and includes claims covering composition of matter and methods of use for DAV132, our innovative product designed to protect the intestinal microbiota in patients taking antibiotics.
This patent reinforces our intellectual property portfolio and comes as a complement to the already 100+ patents protecting DAV132 worldwide.
